You are here

Robust, Efficient Medical Linear Accelerator System

Award Information
Agency: Department of Energy
Branch: N/A
Contract: DE-SC0017687
Agency Tracking Number: 230295
Amount: $149,791.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 08b
Solicitation Number: DE-FOA-0001619
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-06-12
Award End Date (Contract End Date): 2018-03-11
Small Business Information
1713 Stewart Street
Santa Monica, CA 90404-4021
United States
DUNS: 078618369
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Salime Boucher
 (310) 822-5845
Business Contact
 Salime Boucher
Phone: (310) 822-5845
Research Institution
 University of California Los Angeles (UCLA)
 Karla Zepeda
11000 Kinross Avenue Suite 200
Los Angeles, CA 90095-1406
United States

 (310) 206-5202
 Nonprofit College or University

Radiation therapy is used to treat over 60% of cancer patients and is used in nearly half of the curative cases, however, in low- and middle-income countries (LMIC), there is a large underserved population, with technology per capita 2 or more orders of magnitude lower than in the US. Many LMIC still utilize outdated Cobalt-60 machines, which result in excessive normal tissue dose, present safety hazards, and are at risk for diversion for terrorist purposes in radiological dispersal devices (aka “dirty bombs”). The barriers to wider adoption of modern linear accelerator technology are primarily due to the high capital and operating costs and requirement for highly- trained personnel. In addition, state-of-the-art medical linacs have very high peak and average electrical draws, and require stable, reliable power that is often unavailable in LMIC. This project will address these issues with a novel medical linac platform that will be designed from the ground up to be robust, reliable and efficient. The system is based on the novel 4π radiotherapy technique developed at UCLA. It utilizes an industrial robot and allows automatic generation and delivery of high-quality treatment plans. A reliable sparse orthogonal collimator will replace the failure-prone multileaf collimator. Finally, it will incorporate a linear accelerator and RF power system design that is optimized for power efficiency and low cooling requirements. In Phase I of the SBIR project, the efficient accelerating structure and RF power system will be designed and optimized to minimize power consumption and cooling requirements. The simplified, yet clinically superior, sparse orthogonal collimator will be engineered. Finally, the automated treatment planning software will be developed. There is a compelling humanitarian and economic case for increasing access to radiotherapy. Millions die every year in the developing world from cancers that could have been successfully treated by radiation therapy, and it is estimated that the return on investment in radiotherapy can exceed $500 billion globally in 2015-2035 and save 27 million life-years. The team behind this proposal has already started the process of raising private capital for the development of this novel, simple, yet clinically superior radiotherapy system. The business plan projects $674 million in sales during the first 10 years of commercialization. The global radiotherapy equipment market was $4.9 billion in 2014.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government